Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler

Ozturk, Serefnur; Necioglu Orken, Dilek; ARSAVA, E. Murat; ÖZDEMİR, A. Özcan; GÜRKAS, Erdem; TOPÇUOĞLU, M. Akif

Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler

M. Akif TOPÇUOĞLU, (Hacettepe Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

E. Murat ARSAVA, (Hacettepe Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

A. Özcan ÖZDEMİR, (Osmangazi Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Eskişehir, Türkiye)

Erdem GÜRKAS, (Gülhane Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği, Ankara, Türkiye)

Dilek Necioğlu ÖRKEN, (İstanbul Bilim Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Türkiye)

Şerefnur ÖZTÜRK (Selçuk Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Konya, Türkiye Öz)

Türk Nöroloji Dergisi

4 1

Yıl: 2017 Cilt: 23 Sayı: 4 Sayfa Aralığı: 162 - 175 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler

Öz:

Akut iskemik inme tedavisinin kritik elementlerinin başında gelen intravenöz doku plazminojen aktivatörü (tPA) kullanımının yirmi yılı aşkın süre içinde ülkemizde yeterince yaygınlaşamamasının başta gelen nedenlerinden biri, kullanımına dair birçok sorunun yanıtsız kalmasıdır. Ancak, son gelişmeler ile bu soruların pek çoğuna yeterli açıklamanın getirilebilmiş olması önemli bir anlayış değişikliğine yol açmaktadır. Bu makalede akut inmede tPA tedavisi ile ilgili uzmanlarımızın yönelttiği birincil olarak nörolojik sorulara ilişkin yanıt ve açıklamalar mevcut literatür ışığında etraflıca ele alınmış ve herbiri için net tavsiyelerde bulunulmuştur

Anahtar Kelime:

Konular: Nörolojik Bilimler

Intravenous Thrombolytic Therapy in Acute Stroke: Problems and Solutions

Öz:

Use of intravenous tissue plasminogen activator (tPA) is one of the key elements of acute ischemic stroke management. Its use has not become widespread, and has faced significant problems in our country for more than a quarter of a century most probably due to many unanswered questions about issues related with daily practice. However, recent developments, which adequately focused and found solutions for most of these problems and questions, have led to a major change of point of view and understanding of the hyperacute management of stroke. This article, in the light of the relevant literature, discusses and provides clear recommendations for questions directed by neurologists practicing in Turkey mainly about typical neurologic issues faced in the setting of tPA use for acute stroke

Anahtar Kelime:

Konular: Nörolojik Bilimler

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. De Brun A, Flynn D, Joyce K, Ternent L, Price C, Rodgers H, Ford GA, Lancsar E, Rudd M, Thomson RG. Understanding clinicians’ decisions to offer intravenous thrombolytic treatment to patients with acute ischaemic stroke: a protocol for a discrete choice experiment. BMJ Open 2014;4:e005612.
2. Messe SR, Khatri P, Reeves MJ, Smith EE, Saver JL, Bhatt DL, GrauSepulveda MV, Cox M, Peterson ED, Fonarow GC, Schwamm LH. Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry. Neurology 2016;87:1565-1574.
3. Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA. Utilization of intravenous thrombolysis is increasing in the United States. Int J Stroke 2013;8:681-688.
4. Topcuoglu MA, Cekirge HS, Saribas O. Akut iskemik inmede trombolitik tedavi. Turk J Neurol 1997;3:111-119.
5. Kutluk K. Akut iskemik inmede intravenöz trombolitik tedavi: Sorumluluğumuzun farkında mıyız? Türk Serebrovasküler Hastalıklar Dergisi 2009;15:35-39.
6. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
7. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870- 947.
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
9. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
10. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
11. Baatiema L, Otim ME, Mnatzaganian G, de-Graft Aikins A, Coombes J, Somerset S. Health professionals’ views on the barriers and enablers to evidence-based practice for acute stroke care: a systematic review. Implement Sci 2017;12:74.
12. Demaerschalk BM. Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide. Curr Atheroscler Rep 2016;18:53.
13. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, Mishra NK, Shuaib A, Wahlgren NG, Weimar C, Lees KR; VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke 2013;44:727-733.
14. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W; Stroke Thrombolysis Trialists’ Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-1935.
15. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST3]): a randomised controlled trial. Lancet 2012;379:2352-2363.
16. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016;47:581-641.
17. Khatri P, Kleindorfer DO, Yeatts SD, Saver JL, Levine SR, Lyden PD, Moomaw CJ, Palesch YY, Jauch EC, Broderick JP. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke 2010;41:2581-2586.
18. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005;46:243-252.
19. Casaubon LK, Boulanger JM, Blacquiere D, Boucher S, Brown K, Goddard T, Gordon J, Horton M, Lalonde J, LaRivière C, Lavoie P, Leslie P, McNeill J, Menon BK, Moses B, Penn M, Perry J, Snieder E, Tymianski D, Foley N, Smith EE, Gubitz G, Hill MD, Glasser E, Lindsay P; Heart and Stroke Foundation of Canada Canadian Stroke Best Practices Advisory Committee. Canadian Stroke Best Practice Recommendations: Hyperacute Stroke Care Guidelines, Update 2015. Int J Stroke 2015;10:924-940.
20. TCSB. ACTILYSE 50 mg 1 flakon Kullanma Talimatı PDF Dosyası. Erişim adresi: http://wwwilacrehbericom/pdfs/actilyse-50-mg-1-flakon-870d/ kt/ 2012; Erişim tarihi: 21/4/2017 (Boehringer Ingelheim İlaç Tic.A.Ş. Güncelleme: 7 September 2012).
21. Romano JG, Smith EE, Liang L, Gardener H, Camp S, Shuey L, Cook A, Campo-Bustillo I, Khatri P, Bhatt DL, Fonarow GC, Sacco RL, Schwamm LH. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry. JAMA Neurol 2015;72:423-431.
22. Re-examining Acute Eligibility for Thrombolysis Task F, Levine SR, Khatri P, Broderick JP, Grotta JC, Kasner SE, Kim D, Meyer BC, Panagos P, Romano J, Scott P; NINDS rt-PA Stroke Trial Investigators. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms. Stroke 2013;44:2500- 2505.
23. Strbian D, Sairanen T, Rantanen K, Piironen K, Atula S, Tatlisumak T, Soinne L; Helsinki Stroke Thrombolysis Registry Group. Characteristics and outcome of ischemic stroke patients who are free of symptoms at 24 hours following thrombolysis. Cerebrovasc Dis 2011;31:37-42.
24. Machumpurath B, Davis SM, Yan B. Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome. Cerebrovasc Dis 2011;31:278-283.
25. Blinzler C, Breuer L, Huttner HB, Schellinger PD, Schwab S, Köhrmann M. Characteristics and outcome of patients with early complete neurological recovery after thrombolysis for acute ischemic stroke. Cerebrovasc Dis 2011;31:185-190.
26. FDA. ACTIVASE (alteplase) for injection, for intravenous use. HIGHLIGHTS OF PRESCRIBING INFORMATION. Application 103172 This document contains: Label for ACTIVASE. Supplement 5203, Available date: 02/13/2015. Accessed on: 04/20/2017. Available from: https://www. accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf
27. Georgiadis D, Engelter S, Tettenborn B, Hungerbühler H, Luethy R, Müller F, Arnold M, Giambarba C, Baumann CR, von Büdingen HC, Lyrer P, Baumgartner RW. Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis. Circulation 2006;114:237-241.
28. Yalcin-Cakmakli G, Akpinar E, Topcuoglu MA, Dalkara T. Right internal carotid artery occlusion during intravenous thrombolysis for left middle cerebral artery occlusion. J Stroke Cerebrovasc Dis 2009;18:74-77.
29. Cappellari M, Tomelleri G, Carletti M, Bovi P, Moretto G. Intravenous thrombolysis on early recurrent cardioembolic stroke: ‘Dr Jekyll’ or ‘Mr Hyde’? Blood Coagul Fibrinolysis 2012;23:78-81.
30. Qureshi AI, Malik AA, Freese M, Thompson MJ, Khan AA, Suri MF. Readministration of intravenous alteplase in acute ischemic stroke patients: case series and systematic review. Am J Emerg Med 2015;33:307.
31. Brigo F, Bovi T, Tomelleri G, Bovi P, Moretto G. Repeated systemic thrombolysis after early recurrent stroke: always hazardous? Can J Neurol Sci 2012;39:114-116.
32. Sposato LA, Salutto V, Beratti DE, Monti P, Riccio PM, Mazia C. Adverse outcome of early recurrent ischemic stroke secondary to atrial fibrillation after repeated systemic thrombolysis. Case Rep Vasc Med 2013;2013:371642.
33. Alonso de Lecinana M, Fuentes B, Masjuan J, Simal P, Díaz-Otero F, Reig G, Díez-Tejedor E, Gil-Nuñez A, Vivancos J, Egido JA. Thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack. Int J Stroke 2012;7:213-218.
34. Sobolewski P, Brola W, Wiszniewska M, Szczuchniak W, Fudala M, Domagalski M, Sledzińska-Dźwigał M. Intravenous thrombolysis with rt-PA for acute ischemic stroke within 24h of a transient ischemic attack. J Neurol Sci 2014;340:44-49.
35. McKinney JS, Masjuan J, Purroy F, Calvet D, Ay H, Cucchiara BL. Safety of thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack. J Stroke Cerebrovasc Dis 2012;21:551-554.
36. Tsivgoulis G, Sharma VK, Mikulik R, Krogias C, Haršány M, Bavarsad Shahripour R, Athanasiadis D, Teoh HL, Piperidou C, Alexandrov AV. Intravenous thrombolysis for acute ischemic stroke occurring during hospitalization for transient ischemic attack. Int J Stroke 2014;9:413-418.
37. Arsava EM, Topcuoglu MA. De-novo thrombolysis for recurrent stroke in a patient with prior history of thrombolysis. Blood Coagul Fibrinolysis 2010;21:605-607.
38. Matosevic B, Knoflach M, Werner P, Pechlaner R, Zangerle A, Ruecker M, Kirchmayr M, Willeit J, Kiechl S. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology 2013;80:1216- 1224.

APA	TOPÇUOĞLU M, ARSAVA E, ÖZDEMİR A, GÜRKAS E, Necioglu Orken D, Ozturk S (2017). Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. , 162 - 175.
Chicago	TOPÇUOĞLU M. Akif,ARSAVA E. Murat,ÖZDEMİR A. Özcan,GÜRKAS Erdem,Necioglu Orken Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. (2017): 162 - 175.
MLA	TOPÇUOĞLU M. Akif,ARSAVA E. Murat,ÖZDEMİR A. Özcan,GÜRKAS Erdem,Necioglu Orken Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. , 2017, ss.162 - 175.
AMA	TOPÇUOĞLU M,ARSAVA E,ÖZDEMİR A,GÜRKAS E,Necioglu Orken D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. . 2017; 162 - 175.
Vancouver	TOPÇUOĞLU M,ARSAVA E,ÖZDEMİR A,GÜRKAS E,Necioglu Orken D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. . 2017; 162 - 175.
IEEE	TOPÇUOĞLU M,ARSAVA E,ÖZDEMİR A,GÜRKAS E,Necioglu Orken D,Ozturk S "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler." , ss.162 - 175, 2017.
ISNAD	TOPÇUOĞLU, M. Akif vd. "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler". (2017), 162-175.

APA	TOPÇUOĞLU M, ARSAVA E, ÖZDEMİR A, GÜRKAS E, Necioglu Orken D, Ozturk S (2017). Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. Türk Nöroloji Dergisi, 23(4), 162 - 175.
Chicago	TOPÇUOĞLU M. Akif,ARSAVA E. Murat,ÖZDEMİR A. Özcan,GÜRKAS Erdem,Necioglu Orken Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. Türk Nöroloji Dergisi 23, no.4 (2017): 162 - 175.
MLA	TOPÇUOĞLU M. Akif,ARSAVA E. Murat,ÖZDEMİR A. Özcan,GÜRKAS Erdem,Necioglu Orken Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. Türk Nöroloji Dergisi, vol.23, no.4, 2017, ss.162 - 175.
AMA	TOPÇUOĞLU M,ARSAVA E,ÖZDEMİR A,GÜRKAS E,Necioglu Orken D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. Türk Nöroloji Dergisi. 2017; 23(4): 162 - 175.
Vancouver	TOPÇUOĞLU M,ARSAVA E,ÖZDEMİR A,GÜRKAS E,Necioglu Orken D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler. Türk Nöroloji Dergisi. 2017; 23(4): 162 - 175.
IEEE	TOPÇUOĞLU M,ARSAVA E,ÖZDEMİR A,GÜRKAS E,Necioglu Orken D,Ozturk S "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler." Türk Nöroloji Dergisi, 23, ss.162 - 175, 2017.
ISNAD	TOPÇUOĞLU, M. Akif vd. "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sorunlar ve Çözümler". Türk Nöroloji Dergisi 23/4 (2017), 162-175.